NeoGenomics Inc (NEO)
Financial leverage ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | US$ in thousands | 1,681,230 | 1,678,240 | 1,695,110 | 1,709,170 | 1,740,030 | 1,755,580 | 1,792,110 | 1,829,550 | 1,869,780 | 1,906,390 | 1,896,310 | 1,494,410 | 988,331 | 959,428 | 945,485 | 732,247 | 709,506 | 711,155 | 696,667 | 533,343 |
| Total stockholders’ equity | US$ in thousands | 941,537 | 947,428 | 956,192 | 974,462 | 998,023 | 1,012,990 | 1,043,520 | 1,075,000 | 1,108,280 | 1,137,240 | 1,148,360 | 843,714 | 694,294 | 666,363 | 654,229 | 505,043 | 507,408 | 497,007 | 489,734 | 323,848 |
| Financial leverage ratio | 1.79 | 1.77 | 1.77 | 1.75 | 1.74 | 1.73 | 1.72 | 1.70 | 1.69 | 1.68 | 1.65 | 1.77 | 1.42 | 1.44 | 1.45 | 1.45 | 1.40 | 1.43 | 1.42 | 1.65 |
December 31, 2023 calculation
Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $1,681,230K ÷ $941,537K
= 1.79
The financial leverage ratio of Neogenomics Inc. has been relatively stable and increasing gradually over the past several quarters. The ratio has been consistently above 1, indicating that the company relies more on debt financing than equity financing. This could suggest that Neogenomics Inc. has been increasing its debt levels to finance its operations or growth initiatives.
The gradual increase in the financial leverage ratio over time may indicate a growing risk for the company as higher leverage can magnify both returns and losses. It is important for Neogenomics Inc. to carefully manage its debt levels to ensure financial stability and meet its debt obligations.
Overall, monitoring the financial leverage ratio can provide valuable insights into the company's capital structure and risk profile, helping investors and stakeholders assess Neogenomics Inc.'s financial health and sustainability in the long run.